title: Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C.
abstract: BACKGROUND
  Hepatitis C virus (HCV) infected hemophiliacs respond at low rate to interferon (IFN) monotherapy.
  
  
  OBJECTIVE
  To assess efficacy of IFN and RBV in HIV negative hemophiliacs with chronic hepatitis C and identify early predictive factors of response.
  
  
  METHODS
  Twenty naive patients were treated with interferon and RBV for twelve months. Response was assessed by both serial ALT and HCV RNA levels.
  
  
  RESULTS
  Normalization of ALT with clearance of HCV RNA occurred in seven (35%) patients. Age and age at infection were the only features associated with a higher likelihood of response. In all responders the viral load had decreased by at least one log within two months of starting treatment.
  
  
  CONCLUSIONS
  Combination of interferon and ribavirin is well tolerated by hemophiliacs who achieve similar sustained response rates to non-hemophiliacs. Quantitative assessment of viral load at two months of treatment is a useful method to identify non-responders at an early stage.
authors.affiliation: Centre de Transfusió i Banc de Teixits, Servei Català de la Salut, Barcelona, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Sauleda
authors.forename: J I
authors.initials: JI
authors.lastname: Esteban
authors.forename: C
authors.initials: C
authors.lastname: Altisent
authors.forename: L
authors.initials: L
authors.lastname: Puig
authors.forename: R
authors.initials: R
authors.lastname: Esteban
authors.forename: J
authors.initials: J
authors.lastname: Guardia
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D017668:Age of Onset; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D001778:Blood Coagulation Disorders / Q000151:congenital / Q000188:drug therapy / Q000821:virology*; D002648:Child; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005168:Factor VII Deficiency / Q000188:drug therapy / Q000821:virology; D005260:Female; D015483:HIV Antibodies / Q000097:blood; D018023:HIV Seronegativity / Q000187:drug effects*; D006454:Hemoglobins / Q000378:metabolism; D006467:Hemophilia A / Q000188:drug therapy / Q000821:virology; D002836:Hemophilia B / Q000188:drug therapy / Q000821:virology; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000166:cytology; D010976:Platelet Count; D011237:Predictive Value of Tests; D011379:Prognosis; D012367:RNA, Viral / Q000097:blood; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D014842:von Willebrand Diseases / Q000188:drug therapy / Q000821:virology
chemical_list: D000998:Antiviral Agents; D015483:HIV Antibodies; D006454:Hemoglobins; D012367:RNA, Viral; D012254:Ribavirin; D007372:Interferons; D000410:Alanine Transaminase